LENZ Therapeutics Inc [LENZ] stock prices are up 5.07% to $32.53 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The LENZ shares have gain 8.04% over the last week, with a monthly amount glided 9.27%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, TD Cowen started tracking the stock with Buy rating on March 18, 2025, and set its price target to $60. On September 27, 2024, Raymond James initiated with a Outperform rating and assigned a price target of $37 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $38 on August 12, 2024. William Blair initiated its recommendation with a Outperform. Leerink Partners started tracking with a Outperform rating for this stock on April 15, 2024, and assigned it a price target of $32. In a note dated April 10, 2024, Citigroup initiated an Buy rating and provided a target price of $34 on this stock.
The stock price of LENZ Therapeutics Inc [LENZ] has been fluctuating between $16.53 and $38.93 over the past year. Currently, Wall Street analysts expect the stock to reach $51 within the next 12 months. LENZ Therapeutics Inc [NASDAQ: LENZ] shares were valued at $32.53 at the most recent close of the market. An investor can expect a potential return of 56.78% based on the average LENZ price forecast.
Analyzing the LENZ fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.24 and Total Capital is -0.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.33 points at the first support level, and at 30.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 33.26, and for the 2nd resistance point, it is at 33.98.
Ratios To Look Out For
It’s worth pointing out that LENZ Therapeutics Inc [NASDAQ:LENZ]’s Current Ratio is 23.09. As well, the Quick Ratio is 23.09, while the Cash Ratio is 2.69.
Transactions by insiders
Recent insider trading involved Versant Venture Capital VI, L., 10% Owner, that happened on Jun 27 ’25 when 0.2 million shares were sold. 10% Owner, Versant Venture Capital VI, L. completed a deal on Jun 20 ’25 to sell 0.13 million shares. Meanwhile, 10% Owner Versant Venture Capital VI, L. sold 0.1 million shares on Jun 20 ’25.
